Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. USO
7. GOOGL
8. HOOD
9. DFTX
10. IBM

Go back to Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines Inc. (PRAX) PT Raised to $500 at Truist Securities

December 8, 2025 6:26 AM EST

Truist Securities analyst Joon Lee raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $500.00 (from $360.00) while maintaining a Buy rating.

The analyst comments "Vormatrigine reported 100% median seizure reduction at week 8, which was sustained through wk 16 in full Ph2 RADIANT. The results... More